The global antacids market is expected to be worth US$ 6,971.2 million by the end of 2023 and further expand at a CAGR of 4.9% to reach a valuation of US$ 11,194.8 million by 2033.
According to a recent study by Future Market Insights, proton pump inhibitors are leading the market with a share of about 25.8% in the year 2022 within the global market.
Growth in the industry could be attributed to an increase in conditions like heartburn and GERD. The demand for over-the-counter digestive products to treat gastrointestinal disorders is rising as a result of the expanding trend toward self-medication.
| Attribute | Details |
|---|---|
| Antacids Market Size, 2022 | US$ 6,646.9 million |
| Antacids Market Size, 2023 | US$ 6,971.2 million |
| Antacids Market Size, 2033 | US$ 11,194.8 million |
| Value CAGR (2023 to 2033) | 4.9% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
An Increase in the Geriatric Population
Globally, the geriatric population is increasing rapidly, leading to an increase in various clinical conditions like acidity problems. For instance, report published by Economics and Social Affairs, 2020, globally, there were 727 million people 65 years of age or older in 2020. By 2050, it is anticipated that this number will have more than doubled, reaching over 1.5 billion people.
Symptomatic disorders like oesophageal cancer and Barrett's esophagus are relatively common in such people. To cure these diseases, a combination of therapies is implemented, and antacid use in these cases has significantly increased, likely to fuel market expansion throughout the projection period.
Factors Restraining Demand for Antacids
Antacids frequently cause milk-alkali syndrome and dose-dependent rebound hyperacidity as side effects. The detrimental impact of antacids containing aluminum hydroxide cause aluminum poisoning, constipation, osteomalacia, and hypophosphatemia. It is projected that the increasing concerns about these harmful side effects slow the expansion of the market.
Antacids also cause the absorption of other acid-reducing medications when taken with them, which reduces their effectiveness.
The antacids market recorded a growth of around 4.7% and reached a valuation of US$ 6,646.9 million in 2022. The sale of antacids expanded owing to cases of heartburn, gastric ulcers, and ingestion.
| Antacids Market Size, 2022 | US$ 6,646.9 million |
|---|
New drugs that support the market's expansion are being developed by researchers. Eminent market participants make significant contributions to drug development and discovery.
Thus, owing to the factors mentioned above, the global market is expected to grow at a rate of 4.9% during the forecast period from 2023 to 2033
Principal Consultant
| Countries | Market Share |
|---|---|
| United States | 28.1% |
| China | 6.1% |
| India | 4.5% |
| Germany | 6.2% |
| United Kingdom | 5.2% |
The United States holds around 28.1% share of the global market and is projected for continued profitable growth.
The prevalence of gastrointestinal issues is on the rise, and antacid products are becoming widely known among consumers in the United States. However, the availability of effective treatment options and the presence of numerous manufacturers in the United States market has made this one of the key areas in the antacid market.
For instance, in a report published by the Centers for Disease Control and Prevention on 13 September 2021, in the United States, there are 8 million visits to emergency departments when digestive issues are the primary diagnosis as of 2019.
China is set to exhibit a growth rate of nearly 6.1% over the forecast period due to the rise in the geriatric population and the extensive utilization of antacids to relieve GERD-related issues.
One of the world's fastest-growing aging populations is in China. For instance, records stated by the World Health Organization (WHO), By 2040, it is anticipated that 28% of China's population will be over 60. A significant increase in the country's geriatric population has led to China experiencing substantial growth in the artificial tears market.
India is set to exhibit a CAGR of nearly 4.3% globally, with a market share of 4.5% in 2022.
In India, substantial financing and the launch of several healthcare programs, like Pradhan Mantri Jan Arogya Yojana and Ayushman Bharat, which offer accessible healthcare facilities and reimbursement options to patients receiving healthcare treatment, are boosting the demand for the market. Increasing disposable income in middle-class families enables them to spend more money on their healthcare expenditure to get high-quality treatment facilities. The pharmaceutical sector has continuously seen lucrative growth in the Research and Development sector.
| By Drug Class | Market Share |
|---|---|
| Proton Pump Inhibitors | 25.3% |
| H2 Antagonist | 21% |
| Acid Neutralizers | 18.5% |
| Pro-Motility Agents | 8% |
| Anti-H.Pyrolic Drugs | 13.7% |
| Prostaglandin Analogous | 10.3% |
| Others | 3.3% |
Proton pump inhibitors are expected to present high growth at a CAGR of 4.5% by the end of the forecast period, with a market share of 25.3% by the end of 2022. Proton pump inhibitors are a class of medication that reduces the amount of stomach acid produced by glands in the lining of the stomach. Furthermore, it reduces the effects of acid reflux on the lower esophagus.
Tablets hold a market share of 25.5% in 2022 and are expected to display gradual growth over the forecast period, with an estimated CAGR of 4.4% by 2033. Tablets are the easiest way to consume the drug, and it is safe. To treat indigestion and heartburn, antacids work by neutralizing the acid in your stomach. Tablets of antacids cure indigestion and heartburn and work by neutralizing the acid in the stomach
The oral route of administration usage is more as compared to injectables. Oral holds a prominent market share of 64.4% during the year 2022, a CAGR of 4.7% by the end of the forecast period. Owing to its advantages, such as patient compliance, non-invasiveness, and convenience of drug administration, the oral route of administration is the most favored method.
Gastroesophageal reflux disease holds a market share of 49.2% in 2022 and is expected to display gradual growth over the forecast period, with an estimated CAGR of 4.7% in 2033. When stomach acid repeatedly flows back into the tube between the stomach and mouth, it causes gastroesophageal reflux disease. The rising cases of typical GERD symptoms include heartburn, so it holds a prominent position in the market segment.
Retail pharmacies held a prominent market share of 44.0% in 2022, with a CAGR of 4.4% in the forecast period. The prominent market share is expected to be held by retail pharmacies. This is primarily due to the continuing higher dependency on pharmacies, dominant fragment, propelling sales of the overall market. Retail pharmacy stores hold a variety of products of different brands and can be easily located near the residential area, hence gaining the prominent position in the distribution channel based on the share of the market.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The market for the production of antacids is fragmented, with several competitors. These businesses are employing strategies including collaborations, partnerships, mergers and acquisitions, and new drug releases to satisfy consumer demand and increase their client base.
Recent Development
| Attribute | Details |
|---|---|
| Forecast Period | 2018 to 2022 |
| Historical Data Available for | 2023 to 2033 |
| Market Analysis | US$ million for Value |
| Key Regions Covered | North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East & Africa |
| Key Countries Covered | United States, Canada, Brazil, Mexico, Argentina, United Kingdom, Germany, Italy, Russia, Spain, France, BENELUX, Nordic countries, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Turkey, GCC, Israel, South Africa and North Africa |
| Key Market Segments Covered | Drug Class, Dosage Form, Route of Administration, Indication, Distribution Channel and Region |
| Key Companies Profiled |
|
| Pricing | Available upon Request |
The global antacids market was worth US$ 6,646.9 million in 2022.
The rising prevalence of gastric diseases, growing cases of heartburn, and gastric ulcers.
The United States, China, India, Germany, and the United Kingdom are top countries.
The sales revenue of the antacids market is expected to register a 4.9% CAGR.
Johnson and Johnson, Sanofi S.A., Bayer AG, and Sun Pharmaceuticals Ltd are a few key players in the antacids industry.
The United States accounts for about 90.9% of the North American antacids market in 2022.
From 2017 to 2022, the market for antacids expanded at the rate of 3.5%.
India accounts for about 4.3% of market share in 2022 in the antacids market.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Market Round Offs
1.5. FMI Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions/Exclusions
3. Brand Mapping Analysis
3.1. Price v/s Drug Class
3.2. Value for Money
3.3. Top of Mind Antacid Brand
3.4. Brand Portfolio-by Key Players
3.5. Brand Loyalty Mapping
3.6. Route of Administration Pattern Overview
3.7. Branded vs Unbranded-Market Mix
4. Distribution Channel Wise Key Brand Positioning
4.1. Global Top Retailers and their Brand Offerings
4.1.1. Retail Pharmacies
4.1.2. Hospital Pharmacies
4.1.3. Online Pharmacies
4.2. Retail Pricing Strategies
5. Consumer Buying Behavior Analysis
5.1. Functionality and Drug Class Demand
5.1.1. Proton Pump Inhibitors
5.1.2. H2 Antagonist
5.1.3. Acid Neutralizers
5.1.4. Pro-Motility Agents
5.1.5. Anti-H.Pyrolic Drugs
5.1.6. Prostaglandin Analogous
5.1.7. Others
5.2. What factors do you consider when deciding to purchase antacid?
5.3. How important are product certifications when choosing antacid?
5.4. How important is the brand reputation and recognition when selecting antacid?
5.5. What marketing channels do you prefer for learning about new antacid?
5.6. How often do you purchase new antacid?
5.6.1. Once or More Every Month
5.6.2. Once Every 2 months
5.6.3. Once Every 6 Months
5.6.4. Once a Year
5.6.5. Less Than Once A Year
6. Market Trends & Dynamics
6.1. Per capita spending on antacid
6.2. Key Trends Impacting the Market
6.3. Drug Class Innovation / Development Trends
6.3.1. Latest Trends and Demands
6.3.2. Latest Innovations and New Launches
6.4. Future Prospects of
6.5. Market Dynamics
6.5.1. Drivers
6.5.2. Restraints
6.5.3. Opportunity Analysis
7. Value Added Insights
7.1. Drug Class Adoption Analysis
7.2. Diabetes Epidemiology
7.3. New Drug Class Approvals/ Launches
7.4. Regulatory Landscape
7.5. PESTEL Analysis
7.6. Porter’s Analysis
7.7. Value Chain Analysis
8. Market Background
8.1. Macro-Economic Factors
8.1.1. Global GDP Growth Outlook
8.1.2. Global Healthcare Expenditure
8.1.3. Global Gastrointestinal Therapeutics Market Overview
8.2. Forecast Factors - Relevance & Impact
8.2.1. Top Companies Historical Growth
8.2.2. Pharmaceutical spending
8.2.3. Adoption of Antacid
8.2.4. Drug Class Pricing
8.2.5. Drug Class & Stock Availability
8.2.6. Rise in number of stomach ulcer
8.2.7. Companies Increasingly Spending on R&D and Focus on Innovation
8.2.8. Collaborations and Agreements between Manufacturers
9. Global Market Demand (in Value or Size in US$ Million) Analysis 2017 to 2022 and Forecast, 2023 to 2033
9.1. Historical Market Value (US$ Million) Analysis, 2017 to 2022
9.2. Current and Future Market Value (US$ Million) Projections, 2023 to 2033
9.2.1. Y-o-Y Growth Trend Analysis
9.2.2. Absolute $ Opportunity Analysis
10. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Drug Class
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Million) Analysis By Drug Class, 2017 to 2022
10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033
10.3.1. Proton Pump Inhibitors
10.3.2. H2 Antagonist
10.3.3. Acid Neutralizers
10.3.4. Pro-Motility Agents
10.3.5. Anti-H.Pyrolic Drugs
10.3.6. Prostaglandin Analogous
10.3.7. Others
10.4. Market Attractiveness Analysis By Drug Class
11. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Route of Administration
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Million) Analysis By Route of Administration, 2017 to 2022
11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033
11.3.1. oral
11.3.2. Injectable
11.4. Market Attractiveness Analysis By Route of Administration
12. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Dosage Form
12.1. Introduction / Key Findings
12.2. Historical Market Size (US$ Million) Analysis By Dosage Form, 2017 to 2022
12.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Dosage Form, 2023 to 2033
12.3.1. Tablet
12.3.2. Capsules
12.3.3. Powder
12.3.4. Liquid
12.3.5. Others
12.4. Market Attractiveness Analysis By Dosage Form
13. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Indication
13.1. Introduction / Key Findings
13.2. Historical Market Size (US$ Million) Analysis By Indication, 2017 to 2022
13.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Indication, 2023 to 2033
13.3.1. Gastroesophageal Reflux Disease
13.3.2. Heartburn
13.3.3. Peptic Ulcer
13.3.4. Others
13.4. Market Attractiveness Analysis By Indication
14. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Distribution Channel
14.1. Introduction / Key Findings
14.2. Historical Market Size (US$ Million) Analysis By Distribution Channel, 2017 to 2022
14.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033
14.3.1. Retail Pharmacies
14.3.2. Hospital Pharmacies
14.3.3. Online Pharmacies
14.4. Market Attractiveness Analysis By Distribution Channel
15. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Region
15.1. Introduction
15.2. Historical Market Size (US$ Million) Analysis By Region, 2017 to 2022
15.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Region, 2023 to 2033
15.3.1. North America
15.3.2. Latin America
15.3.3. Europe
15.3.4. South Asia
15.3.5. East Asia
15.3.6. Oceania
15.3.7. Middle East & Africa
15.4. Market Attractiveness Analysis By Region
16. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033
16.1. Introduction
16.2. Historical Market Size (US$ Million) and Volume (Units) Trend Analysis By Market Taxonomy, 2017 to 2022
16.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
16.3.1. By Country
16.3.1.1. USA
16.3.1.2. Canada
16.3.2. By Drug Class
16.3.3. By Route of Administration
16.3.4. By Dosage Form
16.3.5. By Indication
16.3.6. By Distribution Channel
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Drug Class
16.4.3. By Route of Administration
16.4.4. By Dosage Form
16.4.5. By Indication
16.4.6. By Distribution Channel
16.5. Market Trends
16.6. Market Drivers & Restraints – Intensity Mapping
16.7. Country Level Analysis & Forecast
16.7.1. USA Market
16.7.1.1. Introduction
16.7.1.2. Market Analysis and Forecast by Market Taxonomy
16.7.1.2.1. By Drug Class Type
16.7.1.2.2. By Route of Administration
16.7.1.2.3. By Dosage Form
16.7.1.2.4. By Indication
16.7.1.2.5. By Distribution Channel
16.7.2. Canada Market
16.7.2.1. Introduction
16.7.2.2. Market Analysis and Forecast by Market Taxonomy
16.7.2.2.1. By Drug Class Type
16.7.2.2.2. By Route of Administration
16.7.2.2.3. By Dosage Form
16.7.2.2.4. By Indication
16.7.2.2.5. By Distribution Channel
17. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033
17.1. Introduction
17.2. Historical Market Size (US$ Million) and Volume (Units) Trend Analysis By Market Taxonomy, 2017 to 2022
17.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
17.3.1. By Country
17.3.1.1. Brazil
17.3.1.2. Mexico
17.3.1.3. Argentina
17.3.1.4. Rest of LATAM
17.3.2. By Drug Class
17.3.3. By Route of Administration
17.3.4. By Dosage Form
17.3.5. By Indication
17.3.6. By Distribution Channel
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Drug Class
17.4.3. By Route of Administration
17.4.4. By Dosage Form
17.4.5. By Indication
17.4.6. By Distribution Channel
17.5. Market Trends
17.6. Market Drivers & Restraints – Intensity Mapping
17.7. Country Level Analysis & Forecast
17.7.1. Brazil Market
17.7.1.1. Introduction
17.7.1.2. Market Analysis and Forecast by Market Taxonomy
17.7.1.2.1. By Drug Class Type
17.7.1.2.2. By Route of Administration
17.7.1.2.3. By Dosage Form
17.7.1.2.4. By Indication
17.7.1.2.5. By Distribution Channel
17.7.2. Mexico Market
17.7.2.1. Introduction
17.7.2.2. Market Analysis and Forecast by Market Taxonomy
17.7.2.2.1. By Drug Class Type
17.7.2.2.2. By Route of Administration
17.7.2.2.3. By Dosage Form
17.7.2.2.4. By Indication
17.7.2.2.5. By Distribution Channel
17.7.3. Argentina Market
17.7.3.1. Introduction
17.7.3.2. Market Analysis and Forecast by Market Taxonomy
17.7.3.2.1. By Drug Class Type
17.7.3.2.2. By Route of Administration
17.7.3.2.3. By Dosage Form
17.7.3.2.4. By Indication
17.7.3.2.5. By Distribution Channel
18. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033
18.1. Introduction
18.2. Historical Market Size (US$ Million) and Volume (Units) Trend Analysis By Market Taxonomy, 2017 to 2022
18.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
18.3.1. By Country
18.3.1.1. UK
18.3.1.2. Germany
18.3.1.3. France
18.3.1.4. Italy
18.3.1.5. Spain
18.3.1.6. BENELUX
18.3.1.7. Russia
18.3.1.8. Rest of Europe
18.3.2. By Drug Class
18.3.3. By Route of Administration
18.3.4. By Dosage Form
18.3.5. By Indication
18.3.6. By Distribution Channel
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Drug Class
18.4.3. By Route of Administration
18.4.4. By Dosage Form
18.4.5. By Indication
18.4.6. By Distribution Channel
18.5. Market Trends
18.6. Market Drivers & Restraints – Intensity Mapping
18.7. Country Level Analysis & Forecast
18.7.1. UK Market
18.7.1.1. Introduction
18.7.1.2. Market Analysis and Forecast by Market Taxonomy
18.7.1.2.1. By Drug Class Type
18.7.1.2.2. By Route of Administration
18.7.1.2.3. By Dosage Form
18.7.1.2.4. By Indication
18.7.1.2.5. By Distribution Channel
18.7.2. Germany Market
18.7.2.1. Introduction
18.7.2.2. Market Analysis and Forecast by Market Taxonomy
18.7.2.2.1. By Drug Class Type
18.7.2.2.2. By Route of Administration
18.7.2.2.3. By Dosage Form
18.7.2.2.4. By Indication
18.7.2.2.5. By Distribution Channel
18.7.3. France Market
18.7.3.1. Introduction
18.7.3.2. Market Analysis and Forecast by Market Taxonomy
18.7.3.2.1. By Drug Class Type
18.7.3.2.2. By Route of Administration
18.7.3.2.3. By Dosage Form
18.7.3.2.4. By Indication
18.7.3.2.5. By Distribution Channel
18.7.4. Spain Market
18.7.4.1. Introduction
18.7.4.2. Market Analysis and Forecast by Market Taxonomy
18.7.4.2.1. By Drug Class Type
18.7.4.2.2. By Route of Administration
18.7.4.2.3. By Dosage Form
18.7.4.2.4. By Indication
18.7.4.2.5. By Distribution Channel
18.7.5. Italy Market
18.7.5.1. Introduction
18.7.5.2. Market Analysis and Forecast by Market Taxonomy
18.7.5.2.1. By Drug Class Type
18.7.5.2.2. By Route of Administration
18.7.5.2.3. By Dosage Form
18.7.5.2.4. By Indication
18.7.5.2.5. By Distribution Channel
18.7.6. BENELUX Market
18.7.6.1. Introduction
18.7.6.2. Market Analysis and Forecast by Market Taxonomy
18.7.6.2.1. By Drug Class Type
18.7.6.2.2. By Route of Administration
18.7.6.2.3. By Dosage Form
18.7.6.2.4. By Indication
18.7.6.2.5. By Distribution Channel
18.7.7. Russia Market
18.7.7.1. Introduction
18.7.7.2. Market Analysis and Forecast by Market Taxonomy
18.7.7.2.1. By Drug Class Type
18.7.7.2.2. By Route of Administration
18.7.7.2.3. By Dosage Form
18.7.7.2.4. By Indication
18.7.7.2.5. By Distribution Channel
19. East Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033
19.1. Introduction
19.2. Historical Market Size (US$ Million) and Volume (Units) Trend Analysis By Market Taxonomy, 2017 to 2022
19.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
19.3.1. By Country
19.3.1.1. China
19.3.1.2. Japan
19.3.1.3. South Korea
19.3.2. By Drug Class
19.3.3. By Route of Administration
19.3.4. By Dosage Form
19.3.5. By Indication
19.3.6. By Distribution Channel
19.4. Market Attractiveness Analysis
19.4.1. By Country
19.4.2. By Drug Class
19.4.3. By Route of Administration
19.4.4. By Dosage Form
19.4.5. By Indication
19.4.6. By Distribution Channel
19.5. Market Trends
19.6. Market Drivers & Restraints – Intensity Mapping
19.7. Country Level Analysis & Forecast
19.7.1. China Market
19.7.1.1. Introduction
19.7.1.2. Market Analysis and Forecast by Market Taxonomy
19.7.1.2.1. By Drug Class Type
19.7.1.2.2. By Route of Administration
19.7.1.2.3. By Dosage Form
19.7.1.2.4. By Indication
19.7.1.2.5. By Distribution Channel
19.7.2. Japan Market
19.7.2.1. Introduction
19.7.2.2. Market Analysis and Forecast by Market Taxonomy
19.7.2.2.1. By Drug Class Type
19.7.2.2.2. By Route of Administration
19.7.2.2.3. By Dosage Form
19.7.2.2.4. By Indication
19.7.2.2.5. By Distribution Channel
19.7.3. South Korea Market
19.7.3.1. Introduction
19.7.3.2. Market Analysis and Forecast by Market Taxonomy
19.7.3.2.1. By Drug Class Type
19.7.3.2.2. By Route of Administration
19.7.3.2.3. By Dosage Form
19.7.3.2.4. By Indication
19.7.3.2.5. By Distribution Channel
20. South Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033
20.1. Introduction
20.2. Historical Market Size (US$ Million) and Volume (Units) Trend Analysis By Market Taxonomy, 2017 to 2022
20.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
20.3.1. By Country
20.3.1.1. India
20.3.1.2. Indonesia
20.3.1.3. Thailand
20.3.1.4. Malaysia
20.3.1.5. Rest of South Asia
20.3.2. By Drug Class
20.3.3. By Route of Administration
20.3.4. By Dosage Form
20.3.5. By Indication
20.3.6. By Distribution Channel
20.4. Market Attractiveness Analysis
20.4.1. By Country
20.4.2. By Drug Class
20.4.3. By Route of Administration
20.4.4. By Dosage Form
20.4.5. By Indication
20.4.6. By Distribution Channel
20.5. Market Trends
20.6. Market Drivers & Restraints – Intensity Mapping
20.7. Country Level Analysis & Forecast
20.7.1. India Market
20.7.1.1. Introduction
20.7.1.2. Market Analysis and Forecast by Market Taxonomy
20.7.1.2.1. By Drug Class Type
20.7.1.2.2. By Route of Administration
20.7.1.2.3. By Dosage Form
20.7.1.2.4. By Indication
20.7.1.2.5. By Distribution Channel
20.7.2. Indonesia Market
20.7.2.1. Introduction
20.7.2.2. Market Analysis and Forecast by Market Taxonomy
20.7.2.2.1. By Drug Class Type
20.7.2.2.2. By Route of Administration
20.7.2.2.3. By Dosage Form
20.7.2.2.4. By Indication
20.7.2.2.5. By Distribution Channel
20.7.3. Thailand Market
20.7.3.1. Introduction
20.7.3.2. Market Analysis and Forecast by Market Taxonomy
20.7.3.2.1. By Drug Class Type
20.7.3.2.2. By Route of Administration
20.7.3.2.3. By Dosage Form
20.7.3.2.4. By Indication
20.7.3.2.5. By Distribution Channel
20.7.4. Malaysia Market
20.7.4.1. Introduction
20.7.4.2. Market Analysis and Forecast by Market Taxonomy
20.7.4.2.1. By Drug Class Type
20.7.4.2.2. By Route of Administration
20.7.4.2.3. By Dosage Form
20.7.4.2.4. By Indication
20.7.4.2.5. By Distribution Channel
21. Oceania Market Analysis 2017 to 2022 and Forecast 2023 to 2033
21.1. Introduction
21.2. Historical Market Size (US$ Million) and Volume (Units) Trend Analysis By Market Taxonomy, 2017 to 2022
21.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
21.3.1. By Country
21.3.1.1. Australia
21.3.1.2. New Zealand
21.3.2. By Drug Class
21.3.3. By Route of Administration
21.3.4. By Dosage Form
21.3.5. By Indication
21.3.6. By Distribution Channel
21.4. Market Attractiveness Analysis
21.4.1. By Country
21.4.2. By Drug Class
21.4.3. By Route of Administration
21.4.4. By Dosage Form
21.4.5. By Indication
21.4.6. By Distribution Channel
21.5. Market Trends
21.6. Market Drivers & Restraints – Intensity Mapping
21.7. Country Level Analysis & Forecast
21.7.1. Australia Market
21.7.1.1. Introduction
21.7.1.2. Market Analysis and Forecast by Market Taxonomy
21.7.1.2.1. By Drug Class Type
21.7.1.2.2. By Route of Administration
21.7.1.2.3. By Dosage Form
21.7.1.2.4. By Indication
21.7.1.2.5. By Distribution Channel
21.7.2. New Zealand Market
21.7.2.1. Introduction
21.7.2.2. Market Analysis and Forecast by Market Taxonomy
21.7.2.2.1. By Drug Class Type
21.7.2.2.2. By Route of Administration
21.7.2.2.3. By Dosage Form
21.7.2.2.4. By Indication
21.7.2.2.5. By Distribution Channel
22. Middle East & Africa Market Analysis 2017 to 2022 and Forecast 2023 to 2033
22.1. Introduction
22.2. Historical Market Size (US$ Million) and Volume (Units) Trend Analysis By Market Taxonomy, 2017 to 2022
22.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
22.3.1. By Country
22.3.1.1. GCC Countries
22.3.1.2. Türkiye
22.3.1.3. South Africa
22.3.1.4. North Africa
22.3.1.5. Rest of MEA
22.3.2. By Drug Class
22.3.3. By Route of Administration
22.3.4. By Dosage Form
22.3.5. By Indication
22.3.6. By Distribution Channel
22.4. Market Attractiveness Analysis
22.4.1. By Country
22.4.2. By Drug Class
22.4.3. By Route of Administration
22.4.4. By Dosage Form
22.4.5. By Indication
22.4.6. By Distribution Channel
22.5. Market Trends
22.6. Market Drivers & Restraints – Intensity Mapping
22.7. Country Level Analysis & Forecast
22.7.1. GCC Countries Market
22.7.1.1. Introduction
22.7.1.2. Market Analysis and Forecast by Market Taxonomy
22.7.1.2.1. By Drug Class Type
22.7.1.2.2. By Route of Administration
22.7.1.2.3. By Dosage Form
22.7.1.2.4. By Indication
22.7.1.2.5. By Distribution Channel
22.7.2. Türkiye Market
22.7.2.1. Introduction
22.7.2.2. Market Analysis and Forecast by Market Taxonomy
22.7.2.2.1. By Drug Class Type
22.7.2.2.2. By Route of Administration
22.7.2.2.3. By Dosage Form
22.7.2.2.4. By Indication
22.7.2.2.5. By Distribution Channel
22.7.3. South Africa Market
22.7.3.1. Introduction
22.7.3.2. Market Analysis and Forecast by Market Taxonomy
22.7.3.2.1. By Drug Class Type
22.7.3.2.2. By Route of Administration
22.7.3.2.3. By Dosage Form
22.7.3.2.4. By Indication
22.7.3.2.5. By Distribution Channel
22.7.4. North Africa Market
22.7.4.1. Introduction
22.7.4.2. Market Analysis and Forecast by Market Taxonomy
22.7.4.2.1. By Drug Class Type
22.7.4.2.2. By Route of Administration
22.7.4.2.3. By Dosage Form
22.7.4.2.4. By Indication
22.7.4.2.5. By Distribution Channel
23. Market Structure Analysis
23.1. Market Analysis by Tier of Companies
23.2. Market Share Analysis of Top Players
23.3. Market Presence Analysis
24. Competition Analysis
24.1. Competition Dashboard
24.2. Branding and Promotional Strategies, By Key Players
24.3. Key Development Analysis
24.4. Competition Deep Dive
24.4.1. Johnson and Johnson
24.4.1.1. Overview
24.4.1.2. Drug Class Portfolio
24.4.1.3. Key Financials
24.4.1.4. Sales Footprint
24.4.1.5. Strategy Overview
24.4.2. Sanofi S.A.
24.4.3. Bayer AG
24.4.4. Sun Pharmaceuticals Ltd
24.4.5. Zydus Lifesciences
24.4.6. Abbott Laboratories
24.4.7. AstraZeneca plc
24.4.8. Boehringer Ingelheim International GmbH
24.4.9. Dr. Reddy’s Laboratories Ltd.
24.4.10. GlaxoSmithKline pl
24.4.11. Pfizer Inc
24.4.12. Procter & Gamble Company
24.4.13. Reckitt Benckiser Group PLC
24.4.14. Takeda Pharmaceutical Company Limited
24.4.15. F. Hoffmann-La Roche Ltd
24.4.16. Mylan N.V
24.4.17. Hikma Pharmaceuticals PLC
24.4.18. Teva Pharmaceutical Industries Ltd.
24.4.19. Bristol Myers Squibb Company
24.4.20. Novartis AG
24.4.21. Lupin, Cipla Inc
24.4.22. Aurobindo Pharma
24.4.23. Fresenius Kabi AG and Alkem Labs
25. Assumptions and Acronyms Used
26. Research Methodology
Explore Healthcare Insights
View Reports
Antacids Market
